When a city opens a bridge before the final load test, commuters reclaim years of lost time and engineers accept a monitoring obligation. That trade, access now in exchange for verification later, is the entire economics of accelerated approval in oncology.

On August 13, 2026, the FDA granted accelerated approval to iberdomide (Zenbexus) with daratumumab/hyaluronidase and dexamethasone, the IberDd regimen, for relapsed or refractory multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent. The approval rests on the two-stage phase 3 EXCALIBER-RRMM trial, in which IberDd produced a minimal residual disease-negative complete response of 41 percent versus 21 percent for the DVd control (P less than .0001).

Three Shifts the Headline Hides

First, MRD negativity is now regulatory currency. With an ODAC unanimous vote endorsing MRD as an early endpoint, the surrogate endpoint economy in myeloma formally matures: smaller, faster, cheaper pivotal trials, and a pipeline that prices depth of response the way equity markets price earnings quality.

Second, the treatment sequence reprices. Rahul Banerjee of Fred Hutchinson Cancer Center frames it plainly: "IberDd is a BCMA-sparing regimen. You can save BCMA targeting for later down the line, or maybe use it after BCMA... IberDd is the way to go." A CELMoD that spares the BCMA axis preserves the bispecific and CAR-T franchise for later lines, and hands community practices, many of which cannot deliver cellular therapy, a potent oral-adjacent option that narrows the access gap between academic and community oncology.

Third, the CELMoD class is being re-rated as mechanistically distinct from IMiDs, which means lenalidomide-refractory status no longer closes the door on this chemistry. For Bristol Myers Squibb, that distinction is commercial oxygen: a second-generation immunomodulatory franchise that lifts the 2026 outlook while competitors reposition their own pipelines.

The Verification Obligation, and Why Sceptics Overreach

Accelerated approval is not full certification: overall survival remains unproven, and the 2021-2023 wave of oncology withdrawals shows regulators will retract access when confirmatory trials lag. That risk deserves a line item. Yet the counter-sceptic case is equally strong: a twenty-point MRD gap with tight confidence intervals is among the deepest surrogate separations in myeloma history, and the unanimous advisory vote signals expert consensus that this bridge was worth opening early.

The 2015 Daratumumab Precedent

Daratumumab's own 2015 accelerated approval, granted on response rates in heavily pretreated patients, converted into one of the most durable confirmatory stories in modern oncology. The lesson is discriminating: surrogates in myeloma have historically validated when the biology is deep, and failed when the margin was thin. EXCALIBER's 41-to-21 ratio sits firmly on the right side of that history.

What Clinics, Payers and Patients Should Do Now

• Community practices should build IberDd pathways now, including MRD testing logistics, before referral pressure forces ad-hoc decisions.
• Payers should design coverage-with-evidence-development clauses rather than blanket prior authorization, capturing data while granting access.
• Patients with lenalidomide-refractory disease should ask whether a BCMA-sparing CELMoD fits before exhausting cellular-therapy options.

February 2027: The Sequence Settles

Six months out, expect NCCN incorporation, early uptake curves that favour community sites, and the first confirmatory-trial interim readouts that will decide whether this accelerated approval becomes the next daratumumab story or a cautionary footnote. The bridge is open; the load test continues.

Primary sources:OncoLive approval report · FDA novel drug approvals 2026